Biosergen publishes interim report for third quarter 2022
Wednesday, November 30, 2022: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the third quarter 2022. The interim report is available as an attached document and on the company website (www.biosergen.net
Summary of the Interim Report for Q3 2022
| 2022 | 2021 | 2022 | 2021 | 2021 | ||
| TSEK | July-Sep | July-Sep | Jan-Sep | Jan-Sep | Jan-Dec | |
| Other income | 493 | 2.652 | 3.219 | 4.653 | 8.573 | |
| Profit/loss before depreciation (EBITDA) | -14.515 | -6.404 | -27.496 | -24.202 | -34.077 | |
| Operating profit/loss befor net financials | -14.515 | -6.404 | -27.496 | -24.202 | -34.077 | |
| Netprofit/loss for the period | -14.499 | -6.550 | -27.474 | -24.359 | -34.318 | |
| Earnings per share (SEK) | -0,51 | -0,40 | -0,97 | -1,51 | -1,22 | |
Highlights during Q3 2022
- August 26, Biosergen completes the third cohort of BSG005 phase 1 trial
- August 31, Biosergen receives a loan of SEK 7 million to finance continued development
- September 2, Biosergen AB: Biosergen’s Board of Directors decides on a rights issue of units of approximately SEK 60.2 million
- September 8, Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study
Highlights after the period
- October 4, Biosergen announces the outcome in the rights issue
The Financial report can be found on our website: https://biosergen.net/investors/filings
